Syngenta announced it will cease selling paraquat in Australia following new regulatory restrictions on the herbicide. The chemical, already banned in over 70 countries, faces increased scrutiny due to links to Parkinson's disease.
Paraquat operates as a fast-acting herbicide widely used in agriculture. Epidemiological research has established associations between paraquat exposure and neurodegenerative disease risk, particularly Parkinson's. The pesticide damages dopamine-producing neurons in the brain, making it a priority for regulatory removal in jurisdictions prioritizing worker and environmental health.
Australia's regulatory shift reflects growing international consensus. The European Union prohibited paraquat in 2018 after a comprehensive risk assessment. Switzerland, Brazil, and China have implemented similar bans. The United States Environmental Protection Agency continues to allow paraquat use, though the agency faced legal pressure from environmental health advocates to reconsider its regulatory stance.
Syngenta's decision precedes formal Australian government action but signals market reality for agrochemical manufacturers. Compliance with emerging regulations reduces legal liability and operational costs compared to defending banned products in court. The company manufactures paraquat under the brand name Gramoxone among others.
Australian farmers currently use paraquat primarily for pre-harvest desiccation of crops and weed control. The herbicide's withdrawal requires adoption of alternative chemical and mechanical weed management strategies. Registered alternatives include glyphosate-based products, though herbicide resistance patterns vary regionally.
Agricultural extension services will need to guide farmers toward replacement products and integrated pest management approaches. The transition period involves retooling equipment and retraining application protocols. Industry groups representing grain producers and horticultural operations have historically resisted restrictions on established herbicides, but market shifts by major manufacturers often precede regulatory mandates.
The withdrawal aligns Australia's practice with occupational health standards already adopted